Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | Director | October 01, 2020 | October 05, 2020 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | May 16, 2024 | May 17, 2024 |
| STRYKER CORPSYK · Entity 369 | President & CEO | February 06, 2012 | February 08, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date October 01, 2020 · Filed October 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,000 |
Reported balance
After 2020-10-01 transaction · row 1
1 source rowRow 1 · 2020-10-01 · Grant · Acquired 498 · Balance 8,000 F1: Restricted stock granted in lieu of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $19,167, divided by the closing price of common stock on the date of grant. This grant represents the equivalent of two months of the board cash retainer as a result of board approval of the restoration of a portion of its cash compensation as disclosed on a Form 8-K dated October 5, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock granted in lieu of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $19,167, divided by the closing price of common stock on the date of grant. This grant represents the equivalent of two months of the board cash retainer as a result of board approval of the restoration of a portion of its cash compensation as disclosed on a Form 8-K dated October 5, 2020.
ILLUMINA, INC.
Report date May 16, 2024 · Filed May 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,129 |
Reported balance
After 2024-05-16 transaction · row 1
1 source rowRow 1 · 2024-05-16 · Grant · Acquired 2,622 · Balance 4,129 F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date.
STRYKER CORP
Report date February 06, 2012 · Filed February 08, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 132,002 |
Reported balance
After 2012-02-06 transaction · row 1
1 source rowRow 1 · 2012-02-06 · Exercise / conversion · Acquired 5,000 · Balance 132,002 |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $46.85 · Expires 2016-02-06 | Direct | 0 |
Reported balance
After 2012-02-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2012-02-06 · Exercise / conversion · Disposed 5,000 · Balance 0 F1: Employee stock option granted pursuant to the Stryker Corporation 1998 Stock Option Plan, exercisable as to 10% on each of the first eight anniversaries of the date of grant and 20% on the ninth anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401k Plan | 716 |
Reported balance
Holding disclosure · report date 2012-02-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 716 |
| Common StockSEC Table I · non-derivative | IndirectAs Custodian | 200 |
Reported balance
Holding disclosure · report date 2012-02-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 200 |
Filing footnotes · ownership attribution and instrument terms
F1: Employee stock option granted pursuant to the Stryker Corporation 1998 Stock Option Plan, exercisable as to 10% on each of the first eight anniversaries of the date of grant and 20% on the ninth anniversary of the date of grant.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HOLOGIC INC
Report date April 07, 2026 · Filed April 09, 2026
Section 16 reporting ended · disclosed 2026-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Disposition to issuer · Disposed 1,423,837 · Balance 0 F1: Includes 1,079,673 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan. F2: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F3: At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and each Company RSU held by the reporting person granted after October 21, 2025 converted into, for each share of Company Common Stock subject to such Company RSU immediately prior to the Effective Time, (i) an unvested award representing the right to receive a cash payment equal to the Cash Consideration, and (ii) an unvested award representing the right to receive cash payments equal to the payments to the holder of one CVR, if any, pursuant to the CVR agreement, in each case, subject to the terms applied to the corresponding Company RSU immediately prior to the Effective Time. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectMacMillan Family Trust | 0 |
Reported balance
After 2026-04-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-04-07 · Disposition to issuer · Disposed 1,146,829 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F4: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.64 · Expires 2026-12-01 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Disposition to issuer · Disposed 160,565 · Balance 0 F5: For Footnote (5), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.85 · Expires 2027-12-01 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-07 · Disposition to issuer · Disposed 159,339 · Balance 0 F5: For Footnote (5), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.85 · Expires 2027-12-01 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-07 · Disposition to issuer · Disposed 768,639 · Balance 0 F5: For Footnote (5), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.97 · Expires 2028-11-12 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-07 · Disposition to issuer · Disposed 151,071 · Balance 0 F5: For Footnote (5), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.61 · Expires 2029-11-11 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-07 · Disposition to issuer · Disposed 152,529 · Balance 0 F5: For Footnote (5), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.35 · Expires 2030-11-09 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-07 · Disposition to issuer · Disposed 123,801 · Balance 0 F5: For Footnote (5), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.13 · Expires 2031-11-08 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-07 · Disposition to issuer · Disposed 118,877 · Balance 0 F5: For Footnote (5), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.35 · Expires 2032-11-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-07 · Disposition to issuer · Disposed 106,300 · Balance 0 F5: For Footnote (5), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.94 · Expires 2033-11-14 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-07 · Disposition to issuer · Disposed 117,829 · Balance 0 F5: For Footnote (5), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.39 · Expires 2034-11-11 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-04-07 · Disposition to issuer · Disposed 117,801 · Balance 0 F5: For Footnote (5), see Remarks below. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 190,400 |
Reported balance
After 2026-04-07 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-04-07 · Grant · Acquired 190,400 · Balance 190,400 F6: Each Hologic restricted stock unit represents a contingent right to receive one share of Company Common Stock. F7: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-04-07 · Disposition to issuer · Disposed 190,400 · Balance 0 F6: Each Hologic restricted stock unit represents a contingent right to receive one share of Company Common Stock. F7: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,079,673 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan.
F2: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
F3: At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and each Company RSU held by the reporting person granted after October 21, 2025 converted into, for each share of Company Common Stock subject to such Company RSU immediately prior to the Effective Time, (i) an unvested award representing the right to receive a cash payment equal to the Cash Consideration, and (ii) an unvested award representing the right to receive cash payments equal to the payments to the holder of one CVR, if any, pursuant to the CVR agreement, in each case, subject to the terms applied to the corresponding Company RSU immediately prior to the Effective Time. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F4: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F5: For Footnote (5), see Remarks below.
F6: Each Hologic restricted stock unit represents a contingent right to receive one share of Company Common Stock.
F7: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU.
TEXAS INSTRUMENTS INC
Report date February 17, 2012 · Filed February 21, 2012
Section 16 reporting ended · disclosed 2012-02-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $1.00 | Direct | 5,899.25 |
Reported balance
After 2012-02-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2012-02-17 · Grant · Acquired 98.3 · Balance 5,899.25 F1: Security converts to common stock on a one-for-one basis. F2: Stock units credited under the Texas Instruments 2009 Director Compensation Plan, to be settled in common stock of the Issuer following the reporting person's termination of service as a director of the Issuer. End-of-period holdings include stock units acquired pursuant to the dividend reinvestment provision of the Plan. |
| Common StockSEC Table I · non-derivative | Direct | 13,977 |
Reported balance
Holding disclosure · report date 2012-02-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,977 |
Filing footnotes · ownership attribution and instrument terms
F1: Security converts to common stock on a one-for-one basis.
F2: Stock units credited under the Texas Instruments 2009 Director Compensation Plan, to be settled in common stock of the Issuer following the reporting person's termination of service as a director of the Issuer. End-of-period holdings include stock units acquired pursuant to the dividend reinvestment provision of the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2019 Filed Nov 13, 2019 22:31 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 126,956 | $46.16 | $5,859,908.09 |
DisclosureSEC source: 0001127602-19-032652 · form4.xml · nonDerivative · entry 3 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,587,415 F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan, which plan was described in the Form 8-K filed by Hologic on June 4, 2019. F4 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $45.93 to $46.51 per share. The Reporting Person will provide, upon request from the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. F2 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 22:31 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 67,440 | $45.44 | $3,064,743.36 |
DisclosureSEC source: 0001127602-19-032652 · form4.xml · nonDerivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,714,371 F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan, which plan was described in the Form 8-K filed by Hologic on June 4, 2019. F3 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $45.265 to $45.92 per share. The Reporting Person will provide, upon request from the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. F2 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 22:31 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 194,396 | $22.29 | $4,333,086.84 |
DisclosureSEC source: 0001127602-19-032652 · form4.xml · nonDerivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,781,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan, which plan was described in the Form 8-K filed by Hologic on June 4, 2019. F2 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 20:53 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 215,996 | $0.00 Strike: $22.29 | $0.00 |
DisclosureSEC source: 0001127602-19-026232 · form4.xml · derivative · entry 4 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,988 Underlying: Common Stock · 215,996 shares Expires 2020-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan, which plan was described in the Form 8-K filed by Hologic on June 4, 2019. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 20:53 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 81,945 | $49.26 | $4,036,938.48 |
DisclosureSEC source: 0001127602-19-026232 · form4.xml · nonDerivative · entry 3 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,587,415 F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan, which plan was described in the Form 8-K filed by Hologic on June 4, 2019. F4 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $48.99 to $49.76 per share. The Reporting Person will provide, upon request by Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (3) and (4) to this Form 4. F2 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 20:53 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 112,451 | $48.41 | $5,444,090.26 |
DisclosureSEC source: 0001127602-19-026232 · form4.xml · nonDerivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,669,360 F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan, which plan was described in the Form 8-K filed by Hologic on June 4, 2019. F3 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $47.985 to $48.97 per share. The Reporting Person will provide, upon request from Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (3) and (4) to this Form 4. F2 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 20:53 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 215,996 | $22.29 | $4,814,550.84 |
DisclosureSEC source: 0001127602-19-026232 · form4.xml · nonDerivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,781,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan, which plan was described in the Form 8-K filed by Hologic on June 4, 2019. F2 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 3,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-029001 · a4.xml · derivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,694 Underlying: Common Stock · 3,102 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: Reflects a value of $115,000 divided by the closing price of common stock on the date of grant. F5 · derivative.exercise_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F5 · derivative.expiration_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-029001 · a4.xml · derivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,592 Underlying: Common Stock · 4,990 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| December 04, 2018 Filed Dec 4, 2018 21:28 UTC | HOLOGIC INC HOLX · Entity 12463 | OtherCommon Stock | 3,424 | $43.90 | $150,313.60 |
DisclosureSEC source: 0001127602-18-035117 · form4.xml · nonDerivative · entry 3 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,565,815 F2 · kind: Shares transferred pursuant to marriage settlement agreement. F3 · price: Closing price per share of Hologic stock on the date of transfer. F1 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:28 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 8,243 | $44.41 | $366,071.63 |
DisclosureSEC source: 0001127602-18-035117 · form4.xml · nonDerivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,569,239 F1 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:28 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 8,452 | $44.41 | $375,353.32 |
DisclosureSEC source: 0001127602-18-035117 · form4.xml · nonDerivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,577,482 F1 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 14, 2018 Filed Nov 14, 2018 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | OtherCommon Stock | 41,770 | $39.82 | $1,663,281.40 |
DisclosureSEC source: 0001127602-18-033029 · form4.xml · nonDerivative · entry 3 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,585,934 F5 · kind: Shares transferred pursuant to marriage settlement agreement. F6 · price: Closing price per share of Hologic stock on the date of transfer. F3 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 151,071 | $0.00 Strike: $40.97 | $0.00 |
DisclosureSEC source: 0001127602-18-033029 · form4.xml · derivative · entry 4 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,071 Underlying: Common Stock · 151,071 shares Expires 2028-11-12 F7 · derivative.exercise_date: This option to purchase common stock becomes exercisable in equal installments on each of the first four anniversaries of the grant date, November 12, 2018. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 24,408 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-033029 · form4.xml · nonDerivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,627,704 F4 · shares: Represents matching restricted stock units granted to the Reporting Person which vest in one installment on the third anniversary of the November 12, 2018 grant date. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F3 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 49,484 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-033029 · form4.xml · nonDerivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,603,296 F1 · shares: Represents restricted stock units which vest in equal installments on each of the first three anniversaries of the grant date, November 12, 2018. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F3 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:07 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionRestricted Stock Unit Award (Right To Receive) · Derivative | 17,348 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-032630 · form4.xml · derivative · entry 3 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,348 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F1 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F3 · derivative.exercise_date: This restricted stock unit award vests in four installments beginning on the first anniversary of the grant date, November 7, 2014. F3 · derivative.expiration_date: This restricted stock unit award vests in four installments beginning on the first anniversary of the grant date, November 7, 2014. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:07 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 5,652 | $41.26 | $233,201.52 |
DisclosureSEC source: 0001127602-18-032630 · form4.xml · nonDerivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,553,812 F2 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:07 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 17,348 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-032630 · form4.xml · nonDerivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,559,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F2 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 21:56 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionRestricted Stock Unit Award (Right To Receive) · Derivative | 15,119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-032439 · form4.xml · derivative · entry 3 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,119 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F7 · derivative.exercise_date: Represents restricted stock units which vest in equal installments on each of the first three anniversaries of the grant date, November 5, 2015. F7 · derivative.expiration_date: Represents restricted stock units which vest in equal installments on each of the first three anniversaries of the grant date, November 5, 2015. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 21:56 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 104,322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-032439 · form4.xml · nonDerivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,542,116 F4 · shares: Represents vested performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan and are voluntarily being reported on Table I. F5 · price: Performance stock units are settled in shares of common stock on a one-for-one basis F6 · balance_after: Includes 1,045,901 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 21:56 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 15,119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-032439 · form4.xml · nonDerivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,437,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vested restricted stock units, the settlement of which has been deferred pursuant to Issuer's Deferred Equity Plan and are voluntarily being reported on Table I. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F3 · balance_after: Includes 941,579 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 3,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009208 · doc4.xml · derivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,602 Underlying: Common Stock · 3,797 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: Reflects a value of $115,000 divided by the closing price of common stock on the date of grant. F5 · derivative.exercise_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F5 · derivative.expiration_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009208 · doc4.xml · derivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,805 Underlying: Common Stock · 6,109 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| December 08, 2017 Filed Dec 8, 2017 21:34 UTC | HOLOGIC INC HOLX · Entity 12463 | OtherCommon Stock | 10,859 | $42.69 | $463,570.71 |
DisclosureSEC source: 0001127602-17-034245 · form4.xml · nonDerivative · entry 4 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,422,675 F5 · kind: Shares transferred pursuant to marriage settlement agreement. F6 · price: Closing price per share of Hologic stock on the date of transfer. F4 · balance_after: Includes 926,460 restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 21:34 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionRestricted Stock Unit Award (Right To Receive) · Derivative | 28,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-034245 · form4.xml · derivative · entry 6 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,040 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F3 · shares: Represents vested restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan and are voluntarily being reported on Table I. F1 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F7 · derivative.exercise_date: This RSU award vests in four installments beginning on first anniversary of the grant date. F7 · derivative.expiration_date: This RSU award vests in four installments beginning on first anniversary of the grant date. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 21:34 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionRestricted Stock Unit Award (Right To Receive) · Derivative | 19,628 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-034245 · form4.xml · derivative · entry 5 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,628 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F1 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F7 · derivative.exercise_date: This RSU award vests in four installments beginning on first anniversary of the grant date. F7 · derivative.expiration_date: This RSU award vests in four installments beginning on first anniversary of the grant date. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 21:34 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 28,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-034245 · form4.xml · nonDerivative · entry 3 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,433,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents vested restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan and are voluntarily being reported on Table I. F1 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F4 · balance_after: Includes 926,460 restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 21:34 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 9,673 | $41.44 | $400,849.12 |
DisclosureSEC source: 0001127602-17-034245 · form4.xml · nonDerivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,405,494 F2 · balance_after: Includes 898,420 restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 21:34 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 19,628 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-034245 · form4.xml · nonDerivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,415,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F2 · balance_after: Includes 898,420 restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:11 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 768,639 | $0.00 Strike: $40.85 | $0.00 |
DisclosureSEC source: 0001127602-17-033910 · form4.xml · derivative · entry 5 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 768,639 Underlying: Common Stock · 768,639 shares Expires 2027-12-01 F4 · derivative.exercise_date: This option to purchase common stock becomes exercisable in equal installments on each of the first four anniversaries of the grant date. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:11 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 159,339 | $0.00 Strike: $40.85 | $0.00 |
DisclosureSEC source: 0001127602-17-033910 · form4.xml · derivative · entry 4 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,339 Underlying: Common Stock · 159,339 shares Expires 2027-12-01 F4 · derivative.exercise_date: This option to purchase common stock becomes exercisable in equal installments on each of the first four anniversaries of the grant date. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:11 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 23,616 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-033910 · form4.xml · nonDerivative · entry 3 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,395,539 F3 · shares: Represents Matching RSUs granted to the Reporting Person which vest in one installment on the third anniversary of the grant date. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F1 · balance_after: Includes 898,420 restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:11 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 50,746 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-033910 · form4.xml · nonDerivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,371,923 F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F1 · balance_after: Includes 898,420 restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:11 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 9,038 | $40.85 | $369,202.30 |
DisclosureSEC source: 0001127602-17-033910 · form4.xml · nonDerivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,321,177 F1 · balance_after: Includes 898,420 restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 21:47 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionPerformance Stock Unit Award (Right to Receive) · Derivative | 277,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-031763 · form4.xml · derivative · entry 10 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 277,564 shares Expires 2017-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: PSUs are settled in shares of common stock on a one-for-one basis upon vesting. F3 · timeliness: Represents vested Performance Stock Units (PSUs) that are subject to deferral pursuant to Issuer's Deferred Equity Plan and are voluntarily being reported on Table I. F4 · price: PSUs are settled in shares of common stock on a one-for-one basis upon vesting. F7 · derivative.exercise_date: These shares represent PSUs awarded to the Reporting Person pursuant to the 2008 Equity Incentive Plan and are subject to vesting as provided in the agreement evidencing the award. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 21:47 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionRestricted Stock Unit Award (Right To Receive) · Derivative | 17,348 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-031763 · form4.xml · derivative · entry 9 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,348 Underlying: Common Stock · 17,348 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: RSUs are settled in shares of common stock on a one-for-one basis upon vesting. F2 · price: RSUs are settled in shares of common stock on a one-for-one basis upon vesting. F8 · derivative.exercise_date: This RSU award vests in four installments beginning on first anniversary of the grant date. F8 · derivative.expiration_date: This RSU award vests in four installments beginning on first anniversary of the grant date. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 21:47 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantPerformance Stock Unit Award (Right to Receive) · Derivative | 138,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-031763 · form4.xml · derivative · entry 8 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,564 Underlying: Common Stock · 138,782 shares Expires 2017-11-07 F4 · derivative.exercise_price: PSUs are settled in shares of common stock on a one-for-one basis upon vesting. F3 · timeliness: Represents vested Performance Stock Units (PSUs) that are subject to deferral pursuant to Issuer's Deferred Equity Plan and are voluntarily being reported on Table I. F4 · price: PSUs are settled in shares of common stock on a one-for-one basis upon vesting. F7 · derivative.exercise_date: These shares represent PSUs awarded to the Reporting Person pursuant to the 2008 Equity Incentive Plan and are subject to vesting as provided in the agreement evidencing the award. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 21:47 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 6,128 | $39.50 | $242,056.00 |
DisclosureSEC source: 0001127602-17-031763 · form4.xml · nonDerivative · entry 5 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330,215 F5 · balance_after: Includes 898,420 shares subject to deferral pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 21:47 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 277,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-031763 · form4.xml · nonDerivative · entry 4 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,336,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · timeliness: Represents vested Performance Stock Units (PSUs) that are subject to deferral pursuant to Issuer's Deferred Equity Plan and are voluntarily being reported on Table I. F4 · price: PSUs are settled in shares of common stock on a one-for-one basis upon vesting. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 21:47 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 17,348 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-031763 · form4.xml · nonDerivative · entry 3 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: RSUs are settled in shares of common stock on a one-for-one basis upon vesting. Read SEC document |
| November 05, 2017 Filed Nov 9, 2017 21:47 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionRestricted Stock Unit Award (Right To Receive) · Derivative | 15,119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-031763 · form4.xml · derivative · entry 7 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,119 Underlying: Common Stock · 15,119 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: RSUs are settled in shares of common stock on a one-for-one basis upon vesting. F1 · timeliness: Represents vested Restricted Stock Units (RSUs) that are subject to deferral pursuant to the Issuer's Deferred Equity Plan and are voluntarily being reported on Table 1. F2 · price: RSUs are settled in shares of common stock on a one-for-one basis upon vesting. F6 · derivative.exercise_date: This RSU award vests in three installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: This RSU award vests in three installments beginning on the first anniversary of the grant date. Read SEC document |
| November 05, 2017 Filed Nov 9, 2017 21:47 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 15,119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-031763 · form4.xml · nonDerivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · timeliness: Represents vested Restricted Stock Units (RSUs) that are subject to deferral pursuant to the Issuer's Deferred Equity Plan and are voluntarily being reported on Table 1. F2 · price: RSUs are settled in shares of common stock on a one-for-one basis upon vesting. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 3,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009506 · doc4.xml · derivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,696 Underlying: Common Stock · 3,790 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: Reflects a value of $100,000 divided by the closing price of common stock on the date of grant. F5 · derivative.exercise_date: Deferred stock units were granted in lieu of 100% of the cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F5 · derivative.expiration_date: Deferred stock units were granted in lieu of 100% of the cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009506 · doc4.xml · derivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,906 Underlying: Common Stock · 7,012 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 827 | $0.00 Strike: $24.92 | $0.00 |
DisclosureSEC source: 0001225208-17-007643 · doc4.xml · derivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827 Underlying: Common Stock · 827 shares Expires 2027-04-03 F4 · shares: Reporting person received 25% of the cash compensation for the first quarter of 2017 in the form of an option to purchase a specified number of shares of common stock vesting in full upon the 2017 annual meeting of stockholders. F4 · derivative.exercise_date: Reporting person received 25% of the cash compensation for the first quarter of 2017 in the form of an option to purchase a specified number of shares of common stock vesting in full upon the 2017 annual meeting of stockholders. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 677 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-007643 · doc4.xml · derivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,894 Underlying: Common Stock · 677 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $16,875 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Deferred stock units were granted in lieu of 75% of the quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Deferred stock units were granted in lieu of 75% of the quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| March 01, 2017 Filed Nov 9, 2017 21:47 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionRestricted Stock Unit Award (Right To Receive) · Derivative | 237,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-031763 · form4.xml · derivative · entry 6 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 237,500 shares Expires 2017-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: RSUs are settled in shares of common stock on a one-for-one basis upon vesting. F1 · timeliness: Represents vested Restricted Stock Units (RSUs) that are subject to deferral pursuant to the Issuer's Deferred Equity Plan and are voluntarily being reported on Table 1. F2 · price: RSUs are settled in shares of common stock on a one-for-one basis upon vesting. Read SEC document |
| March 01, 2017 Filed Nov 9, 2017 21:47 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 237,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-031763 · form4.xml · nonDerivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · timeliness: Represents vested Restricted Stock Units (RSUs) that are subject to deferral pursuant to the Issuer's Deferred Equity Plan and are voluntarily being reported on Table 1. F2 · price: RSUs are settled in shares of common stock on a one-for-one basis upon vesting. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 814 | $0.00 Strike: $21.88 | $0.00 |
DisclosureSEC source: 0001225208-17-000782 · doc4.xml · derivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 814 Underlying: Common Stock · 814 shares Expires 2027-01-03 F4 · shares: Reporting person received 25% of the cash compensation for the fourth quarter of 2016 in the form of an option to purchase a specified number of shares of common stock vesting in full upon the 2017 annual meeting of stockholders. F4 · derivative.exercise_date: Reporting person received 25% of the cash compensation for the fourth quarter of 2016 in the form of an option to purchase a specified number of shares of common stock vesting in full upon the 2017 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.